Category Archives: Biotech

Bureaucratic Roadblocks Threaten Biopharma Growth

Ahead of the BIO International Convention next week, Jim Greenwood, President and CEO of the Biotechnology Industry Organization, writes that protecting intellectual property rights is vital to biopharma innovation. There is a clear link between a country’s rate of economic development and the strength of its intellectual property laws. This is particularly true in knowledge-intensive […]
Also posted in FDA, Guest Blog, IP, Regulatory | Tagged , , , , | Leave a comment

Challenges to the Specialty Business Model

By Emily O’Connor, Jillian Scaife, and Ryan P. Million Biopharmaceutical drug discovery companies have progressively tailored their pipelines to specialty therapeutic areas and smaller patient populations. However, the specialty business model has lately shown signs of strain and outright constraints in continued scalability. Agents such as Gleevec, Zaltrap, and Sovaldi have been under fire from […]
Also posted in Market Access, Strategy | Tagged , , , | Leave a comment

Increase of Biosimilars Will Have “Negative Impact”

A new report from GlobalData states that the increase of biosimilars will have a negative impact on the biologics market after 2019. The report cites patent expirations of branded biologics and regulatory clarification as reasons for the prediction that biosimilars will capture the market share after 2019.
Also posted in Events, Gene therapy, Global | Tagged , , | Leave a comment

What Does ‘Off Label’ Mean in 2014?

by Tom Norton Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s […]
Also posted in FDA, Guest Blog, healthcare, Legal, Market Access, Marketing, pricing, Regulatory, Strategy | Tagged , , | 1 Comment

Q&A: Nathan Tinker, New York Biotechnology Association

While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association, about challenges in early phase development. The New York Biotechnology Association is dedicated to the development and growth of New York State-based bioscience related industries and institutions. Moe Alsumidaie: How […]
Also posted in People | Tagged , , , | Leave a comment
  • Categories

  • Meta